The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma-Reference-Cited by-同舟云学术

The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma

Published:2010-11-15 Issue:10 Volume:10 Page:1009-1018
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Hector Alvarez,Montgomery Elizabeth A.,Karikari Collins,Canto Marcia I.,Dunbar Kerry B.,Wang Jean S.,Feldmann Georg,Hong Seung-Mo,Haffner Michael C.,Meeker Alan K.,Holland Sacha J.,Yu Jiaxin,Heckrodt Thilo J.,Zhang Jing,Ding Pingyu,Goff Dane,Singh Rajinder,Roa Juan Carlos,Marimuthu Arivusudar,Riggins Gregory J.,Eshleman James R.,Nelkin Barry D.,Pandey Akhilesh,Maitra Anirban

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

http://www.tandfonline.com/doi/pdf/10.4161/cbt.10.10.13248

Reference38 articles.

1. Esophageal adenocarcinoma arising in Barrett esophagus

2. Screening, Surveillance, and Prevention for Esophageal Cancer

3. Preoperative Therapy for Esophageal Cancer

4. Using the transcriptome to annotate the genome

5. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Altered expression of AXL receptor tyrosine kinase in gastrointestinal cancers: a promising therapeutic target;Frontiers in Oncology;2023-07-04

2. AXL, along with PROS1, is overexpressed in papillary thyroid carcinoma and regulates its biological behaviour;World Journal of Surgical Oncology;2022-10-06

3. AXL Promotes Metformin-Induced Apoptosis Through Mediation of Autophagy by Activating ROS-AMPK-ULK1 Signaling in Human Esophageal Adenocarcinoma;Frontiers in Oncology;2022-07-22

4. Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition;Frontiers in Immunology;2022-04-27

5. Combined OPCML and AXL Expression as a Prognostic Marker and OPCML Enhances AXL Inhibitor in Cholangiocarcinoma;In Vivo;2022